Comparison of Clinical Efficacy of Submucosal Dexamethasone and Oral Trypsin-chymotrypsin for Reduction of Postoperative Sequelae After Lower Third Molar Surgery

NCT ID: NCT06713733

Last Updated: 2024-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-25

Study Completion Date

2025-01-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pain, edema and trismus are the most frequent postoperative sequelae to surgical removal of impacted teeth, all of are due to the local inflammatory response.

Use of corticosteroids decrease tissue mediators of inflammation and reduce edema.

Use of trypsin-chymotrypsin elaborates the enzymes esterase in blood plasma that inhibits inflammation by hydrolytic degradation of the inflammatory peptides.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Impacted tooth is a tooth which is completely or partially unerupted and is positioned against another tooth, bone or soft tissue so that its further eruption is unlikely, described according to its anatomic position.

Surgical extraction of the impacted mandibular third molars is the most common procedure in oral surgery clinics. Most of the common postoperative complications following lower third molars surgery are pain, trismus and facial swelling. Adequate surgical methods such as selecting an appropriate flap design, minimal bone removal and less trauma to adjacent soft tissues with proper wound closure techniques could decrease the incidence of postoperative sequelae, but not eliminate it.

surgical edema is expected sequel of removal of impacted lower wisdom tooth. Swelling usually reaches at its maximum on 2nd and 3rd postoperatively day and should start reducing by 4th day. Swelling completely resolves by the 7th to 9th day.

Corticosteroids are routinely employed to control the sequelae of inflammation in third molar surgeries. Steroids prevent diapedesis, the initial leakage of fluids from the capillaries, and stabilize the membranes of the cellular lysosomes which hold large quantities of hydrolytic enzymes. There is also a decrease in the formation of bradykinin, a powerful vasodilating substance. Steroids act by suppression of leucocyte and macrophage accumulation at the inflammatory site by interfering with capillary dilatation, fibrin deposition and prevention of prostaglandin synthesis by inhibiting the arachidonic acid cascade.

Trypsin-chymotrypsin is proteolytic enzymes that acts as anti-inflammatory agents. The concentration of enzymes determined as esterase in blood plasma is increased after trypsin chymotrypsin administration. Since the inflammatory process is thought to be due to peptides elaborated at the site of tissue trauma, it has been postulated that the increased blood esterase due to trypsin chymotrypsin administration inhibits inflammation by hydrolytic degradation of the inflammatory peptides.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Clinical Efficacy of Submucosal Dexamethasone and Oral Trypsin Chymotrypsin for Reduction of Postoperative Sequelae After Lower Third Molar Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

group a - submucosal dexamethasone group b - oral trypsin chymotrypsin
Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Investigators
PI does not have access to any of the groups. i.e PI is blinded.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexamethasone

submucosal dexamethasone is quite simple, less invasive, painless, convenient for the surgeon and offers a low cost solution. Submucosal injection offers advantage of concentrating the drug near the surgical area with less systemic absorption and no further manipulation of the tissues.

preoperative submucosal dexamethasone 8mg prior to incision locally.

Group Type ACTIVE_COMPARATOR

Dexamethasone

Intervention Type DRUG

local infiltration

Chymotrypsin

oral trypsin chymotrypsin is proteolytic enzymes.

1 tab given 30 minutes prior to incision and 1 tab for three times a day for 5 days after extraction.

Group Type ACTIVE_COMPARATOR

Chymotrypsin

Intervention Type DRUG

orally given

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexamethasone

local infiltration

Intervention Type DRUG

Chymotrypsin

orally given

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

submucosal dexamethasone oral trypsin chymotrypsin

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinically healthy patients (ASA I) patient free of any systemic diseases that could interfere with wound healing or surgical operation.
* Free of any recent anti-inflammatory drug intake or being under long term treatment with medicaments that will obscure the assessment of the inflammatory response as NSAIDs, steroids, or antihistamines
* Free from allergy to the drugs used in the study
* Patients requiring surgical removal of the mandibular impacted third molar

Exclusion Criteria

* Patients who are ASA II to ASA VI.
* Patients already on corticosteroids through any route.
* Patients with known allergy to any drugs.
* Pregnant and lactating females
* Patient not consenting to participate in the study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

B.P. Koirala Institute of Health Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

DR. SABIN BANIYA

DR.SABIN BANIYA

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bp Koirala Institute of Health Sciences

Dharān, Koshi, Nepal

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Nepal

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

sabin baniya, mds

Role: CONTACT

+977-9841134900

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

BP KOIRALA INSTITUTE OF HEALTH SCIENCES

Role: primary

+977-9802330760

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRC/2765/024

Identifier Type: -

Identifier Source: org_study_id